stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) Book value per share
CareDx, Inc.'s book value per share at the end of fiscal 2025 was 5.7×, down 20.7% from 7.2× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 9.0×. Over the past ten years it has ranged from −0.3× (fiscal 2017) to 8.9× (fiscal 2021); the current reading is higher than 64% of that period. CareDx, Inc. ranks 22nd of 49 Diagnostics & Research companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 5.7× | (20.68%) |
| FY2024 | 7.2× | 47.53% |
| FY2023 | 4.9× | (39.85%) |
| FY2022 | 8.1× | (9.38%) |
| FY2021 | 8.9× | 49.28% |
| FY2020 | 6.0× | 154.35% |
| FY2019 | 2.3× | (12.74%) |
| FY2018 | 2.7× | — |
| FY2017 | −0.3× | — |
| FY2016 | 1.2× | (51.83%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 9.0× | 8.47% |
| Jun 2026 | 8.3× | 34.90% |
| Mar 2026 | 6.1× | 7.76% |
| Dec 2025 | 5.7× | (4.01%) |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| GRAL GRAIL, Inc. compare | 52.5× |
| RDNT RadNet, Inc. compare | 17.9× |
| VCYT Veracyte, Inc. compare | 17.8× |
| CDNA CareDx, Inc. | 9.0× |
| WGS GeneDx Holdings Corp. compare | 8.2× |
| NEO NeoGenomics, Inc. compare | 6.2× |
| SHC Sotera Health Company compare | 2.6× |
| ADPT Adaptive Biotechnologies Corporation compare | 1.1× |
| BLLN BillionToOne, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement